Pharmacotherapy of recurrent respiratory papillomatosis: An expert opinion

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 4, 2009, Pages 645-655

  Gallagher, Thomas Q ^b   Derkay, Craig S ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

Author keywords

Acyclovir; Cidofovir; HPV vaccine; HspE7; Human papilloma virus (HPV); Indole 3 carbinol; Interferon; Recurrent respiratory papillomatosis (RRP); Retinoids

Indexed keywords

3 INDOLEMETHANOL; ACICLOVIR; CELECOXIB; CIDOFOVIR; CIMETIDINE; HSPE7 VACCINE; ISOTRETINOIN; PEGINTERFERON ALPHA2A; PLACEBO; PROBENECID; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE; ZINC; ANTIVIRUS AGENT;

ADJUVANT THERAPY; ALOPECIA; CHAPPED LIPS; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DIET THERAPY; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; DYSPLASIA; FATIGUE; FEBRILE CONVULSION; FEVER; FLU LIKE SYNDROME; GROWTH RETARDATION; GYNECOMASTIA; HEAD AND NECK TUMOR; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; LEUKOPENIA; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MALIGNANT TRANSFORMATION; MEDLINE; NAUSEA AND VOMITING; NONHUMAN; PAPILLOMATOSIS; PREVALENCE; PRURITUS; RASH; RECURRENT DISEASE; RECURRENT RESPIRATORY PAPILLOMATOSIS; RESPIRATORY TRACT DISEASE; RETICULOCYTOSIS; RETINITIS; REVIEW; SIDE EFFECT; SKIN EXFOLIATION; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; VIRUS INFECTION; WART VIRUS; ADJUVANT CHEMOTHERAPY; ADULT; CHILD; ISOLATION AND PURIFICATION; LARYNX TUMOR; PAPILLOMA; PAPILLOMA VIRUS; PATHOLOGY; PHYSIOLOGY; TUMOR RECURRENCE;

ADULT; ANTIVIRAL AGENTS; CHEMOTHERAPY, ADJUVANT; CHILD; HUMANS; LARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PAPILLOMA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 65649092625     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902793530     Document Type: Review

References (79)

1. Hobbs CG, Birchall MA. Human papillomavirus infection in the etiology of laryngeal carcinoma. Curr Opin Otolaryngol Head Neck Surg 2004;12:88-92 • Excellent review of the role of HPV in head and neck cancer. (Pubitemid 38420195)
2. Leung R, Hawkes M, Campisi P. Severity of juvenile onset recurrent respiratory papillomatosis is not associated with socioeconomic status in a setting of universal health care. Int J Pediatr Otorhinolaryngol 2007;71:965-972 (Pubitemid 46670359)
3. Bitar M, Baz R, Fuleihan N, Muallem M. Can zinc be an adjuvant therapy for juvenile onset recurrent respiratory papillomatosis? Int J Pediatr Otorhinolaryngol 2007;71:1163-1173
4. Wiatrak BJ. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg 2003;11:433-441 (Pubitemid 37468156)
5. Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004;114(Suppl 104):1-23 •• Seminal study regarding the role of HPV subtyping in predicting severity of disease. (Pubitemid 39535733)
6. Derkay C, Darrow D. Recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2006;115(1):1-11 (Pubitemid 43132434)
7. Shykhon M, Kuo M, Pearman K. Recurrent respiratory papillomatosis. Clin Otolaryngol Allied Sci 2002;27(4):237-243 (Pubitemid 36005527)
8. Derkay CS. Task force on recurrent respiratory papillomas: a preliminary report. Arch Otolaryngol Head Neck Surg 1995;121:1386-1391 • Largest survey to date of juvenile-onset RRP patients used to estimate prevalence and incidence.
9. Reeves WC, Ruparelia SS, Swanson KI, et al. National registry for juvenile-onset respiratory apillomatosis. Arch Otolaryngol Head Neck Surg 2003;129(9):976-982 •• CDC collaboration to estimate prevalence and incidence of RRP in the United States. (Pubitemid 37087659)
10. Weller SC, Stanberry LR. Estimating the population of HPV. JAMA 2007;297(8):876-878
11. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297(8):813-819 (Pubitemid 46333946)
12. Shah K, Kashima H, Polk F, et al. Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol 1986;68:795-799 • Seminal study examining the role of mode of delivery with transmission of RRP. (Pubitemid 17190219)
13. Stern Y, Felipovich A, Cotton R, Segal K. Immunocompetency in children with recurrent respiratory papillomatosis: prospective study. Ann Otol Rhinol Laryngol 2007;116(3):169-171 (Pubitemid 46452452)
14. Schraff S, Derkay CS. Survey of ASPO membership regarding management of RRP distal spread and the use of adjuvant therapies. Arch Otolaryngol Head Neck Surg 2004;130:1039-1042 • Largest survey of current practice patterns for managing RRP.
15. Sen G. Mechanism of interferon action: progress toward its understanding. Prog Nucleic Acid Res Mol Biol 1982;27:101-156
16. Derkay C, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008;118(7):1236-1247 •• Comprehensive review of the RRP literature.
17. Gerein V, Rastorguev E, Gerein J, et al. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005;114(6):463-471 (Pubitemid 40840078)
18. Chadha NK, James AL. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. Otolaryngol Head Neck Surg 2007;136(6):863-869 •• Systematic review of the literature regarding adjuvant therapies for RRP. (Pubitemid 46843352)
19. Rimmell F, Shoemaker D, Pu A, et al. Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors. Laryngoscope 1997;107:915-918 (Pubitemid 27284317)
20. Pou A, Rimmell F, Jordan J, et al. Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Ann Otol Rhinol Laryngol 1995;104:758-762
21. Kiroglu M, Cetik F, Soylu L, et al. Acyclovir in the treatment of recurrent respiratory papillomatosis: a preliminary report. Am J Otolaryngol 1994;15(3):212-214 (Pubitemid 24138442)
22. Endres D, Bauman N, Burke D, et al. Acyclovir in the treatment of recurrent respiratory papillomatosis. A pilot study. Ann Otol Rhinol Laryngol 1994;103:301-305 (Pubitemid 24134102)
23. Lopez Aguado D, Perez Pinero B, Betancor L, et al. Acyclovir in the treatment of laryngeal papillomatosis. Int J Pediatr Otorhinolaryngol 1991;21(3):269-274
24. McGlennen R, Adams G, Lewis C, et al. Pilot trial of ribavirin for the treatment of laryngeal papillomatosis. Head Neck 1993;15:504-513 (Pubitemid 23304987)
25. Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope 2003;113:1583-1587 • First successful report in children of use of cidofovir for treatment of severe RRP. (Pubitemid 37087843)
26. Mandell DL, Arjman EM, Kay DJ, et al. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2004;130(11):1319-1323 (Pubitemid 39532268)
27. Co J, Woo P. Office based intralesional injection of cidofovir in adult-onset RRP. Ann Otol Rhinol Laryngol 2004;113:859-862
28. Tasca R, McCormick M, Clarke R. British Association of Paediatric Otorhinolaryngology members experience with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2006;70(7):1183-1187 (Pubitemid 43766769)
29. Donne AJ, Hampson L, Rothera MP, et al. Effects of cidofovir on a novel cell-based test system for recurrent respiratory papillomatosis. Head Neck 2007;9(8):741-750 (Pubitemid 47265529)
30. McMurray JS, Conner N, Ford C. Cidofovir efficacy in RRP: a prospective blinded placebo-controlled study 2008. Ann Otol Rhinol Laryngol 2008;117(7):477-483
31. Derkay CS. Cidofovir for recurrent respiratory papillomatosis (RRP): a re-assessment of risks. Int J Pediatr Otorhinolaryngol 2005;69(11):1465-1467 • RRP Task Force recommendations on the use of cidofovir.
32. Naiman A, Roger G, Gagnieu MC, et al. Cidofovir plasma assays after local injection in respiratory papillomatosis. Laryngoscope 2004;114:1151-1156 • Analysis of the potential for cidofovir to cause systemic side effects after local injection. (Pubitemid 38954565)
33. Available from: http://www.fda.gov/cder/foi/adcomm/96/avdac-joint-031496- summmin-ac.pdf
34. Lacy S, Hitchcock M, Lee W, et al. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 1998;44(2):97-106 (Pubitemid 28415221)
35. Broekema F, Dikkers F. Side-effect of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2008;265:871-879
36. Lindsay F, Bloom D, Pransky S, et al. Histologic review of cidofovir-treated recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2008;117(2):11-117 • Retrospective histologic analysis of tissue specimens from children treated with cidofovir demonstrating a lack of atypia. (Pubitemid 351287914)
37. Wu R, Coniglio SJ, Chan A, et al. Up-regulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas. Mol Med 2007;13(3-4):143-150 (Pubitemid 46944956)
38. Wu R, Abramson AL, Shikowitz MJ, et al. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. Clin Cancer Res 2005;11(17):6155-6161 (Pubitemid 41262942)
39. Eicher S, Taylor-Cooley L, Donovan D. Isoretinoin therapy for recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 1994;120:405-409 (Pubitemid 24129005)
40. Osborne C, LeBoeuf H, Jones D. Isotretinoin in respiratory papillomatosis. Ann Intern Med 2000;132:1007 (Pubitemid 30397609)
41. Avidano M, Singleton G. Adjuvant drug strategies in the treatment of recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1995;112:197-202
42. Bell R, Hong W, Itri L, et al. The use of cis-retinoic acid in recurrent respiratory papillomatosis of the larynx: a randomized pilot study. Am J Otolaryngol 1988;9:161-164 (Pubitemid 18259671)
43. McKenna M, Brodsky L. Extraesophageal acid reflux and recurrent respiratory papilloma in children. Int J Pediatr Otorhinolaryngol 2005;69:597-605 (Pubitemid 40585772)
44. Borkowski G, Sommer P, Stark T, et al. Recurrent respiratory papillomatosis associated with gastroesophageal reflux disease in children. Eur Arch Otorhinolarnygol 1999;256:370-372 (Pubitemid 29427905)
45. Holland B, Koufman J, Postma G, McGuirt W. Laryngopharyngeal reflux and laryngeal web formation in patients with pediatric recurrent respiratory papillomas. Laryngoscope 2002;112:1926-1929 (Pubitemid 35283449)
46. Orlow S, Paller A. Cimetidine therapy for multiple viral warts in children. J Am Acad Dermatol 1993;28:794-796 (Pubitemid 23133400)
47. Glass A, Slomon B. Cimetidine therapy for recalcitrant warts in adults. Arch Dermatol 1996;132:680-682 (Pubitemid 26174109)
48. Allen A, Siegfried E. What's new in human papillomavirus infection. Curr Opin Pediatr 2000;12:365-369 (Pubitemid 30470130)
49. Harcourt JP, Worley G, Leighton SE. Cimetidine treatment for recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 1999;51(2):109-113 (Pubitemid 29512284)
50. Fraker P, King L, Laakko T, Vollmer T. The dynamic link between the integrity of the immune system and zinc status. J Nutr 2000;130:S1399-406 (Pubitemid 30244137)
51. Dardenne M. Zinc and immune function. Eur J Clin Nutr 2002;56:S20-23 (Pubitemid 34905966)
52. Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R. Estrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 1989;70:2227-2232 (Pubitemid 19215129)
53. Bradlow H, Michnovicz J, Telang N, Osborne M. Effect of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 1991;12:1571-1574
54. Newfield L, Goldsmith A, Bradlow H, et al. Estrogen metabolism and human papillomavirus-induced tumors of the larynx: chemoprophylaxis with indole-3-carbinol. Anticancer Res 1993;13:337-342 (Pubitemid 23196766)
55. Rosen C, Bryson P. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 2004;18:248-253 (Pubitemid 38757553)
56. Derkay C, Smith R, Mcclay J, et al. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol 2005;114(9):730-737 (Pubitemid 41356111)
57. FUTURE II Study Group. Quadrivalent vaccine against HPV to prevent high-grade cervical lesions. N Engl J Med 2007;356;1915-1927 • Data supporting the efficacy of the quadrivalent HPV vaccine to prevent high-grade cervical lesions and cervical cancer.
58. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent HPV (types 6,11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multi-centre phase II efficacy trial. Lancet Oncol 2005;6:271-278 • Data supporting the efficacy of the quadrivalent HPV vaccine to prevent high-grade cervical lesions and cervical cancer.
59. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent HPV: recommendations of the ACIP, 23 March 2007. Available from: http://www.cdc.gov/ nip/vaccine/hpv
60. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivaletn HPV types 6,11, 16 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr Infec Dis J 2007;26:201-209
61. May J. HPV vaccination-a paradigm shift in public health. Aust Fam Physician 2007;36:106-111
62. Giuliano AR. Human papillomavirus vaccination in males. Gynecol Oncol 2007;107:S24-6 (Pubitemid 47559076)
63. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med 2006;355:2389-2391 (Pubitemid 44903743)
64. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenecity of a prophylactic quadrivalent human papillomavirus (types 6,11, 16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-2145
65. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papilloma vaccination strategies. Emerg Infect Dis 2007;13:28-41 (Pubitemid 46057835)
66. Tissot AM, Zimet GD, Rosenthal SL, et al. Effective strategies for HPV vaccine delivery: the views of pediatricians. J Adolesc Health 2007;41:119-125 (Pubitemid 47058987)
67. Kahn JA, Rosenthal SL, Tissot AM, et al. Factors influencing pediatricians' intentions to recommend human papillomavirus vaccines. Ambul Pediatr 2007;7:367-373 (Pubitemid 47387117)
68. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like particle vaccine against infection with HPV types 16 and 18 in young women: an interim analysis of a phase II double-blind, randomized controlled trial. Lancet 2007;369:2161-2170 • Data suggesting that the prophylactic HPV vaccine in its current form is not effective in clearing established HPV infection. (Pubitemid 46977438)
69. Pederson C, Petaja T, Strauss G, et al. Immunization of early adolescent females with HPV type 16 and 18 L1 virus-like particle vaccine containing ASO4 adjuvant. J Adolesc Health 2007;40:564-571 (Pubitemid 46771257)
70. Freed GL. Derkay CS. Prevention of RRP: the role of HPV vaccination. Int J Pediatr Otorhinolaryngol 2007;70:1799-1803
71. Hildesheim A, Herrero R, Washolder S, et al. Effect of HPV 16/18 L1 virus-like particle vaccine among young women with preexisting infection. JAMA 2007;298:743-753
72. Markowitz L. HPV vaccines: prophylactic, not therapeutic. JAMA 2007;298:805-806 (Pubitemid 47263164)
73. Badaracco G, Venuti A. HPV therapeutic vaccines in head and neck tumors. Expert Rev Anticancer Ther 2007;7:753-766
74. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956 (Pubitemid 46740304)
75. Syrjanen S. HPV in head and neck cancer. J Clin Virol 2005;32(Suppl 1):S59-66
76. Kawana K, Yasugi T, Yoshikawa H, et al. Evidence for the presence of neutralizing antibodies against HPV type6 in infants born to mothers with condylomata. Am J Perinatol 2003;20:11-16
77. Schaffer A, Brotherton J, Booy R. Do HPV vaccines have any role in newborns and the prevention of RRP in children? J Paediatr Child Health 2007;43:579-580
78. Chadha N, James A. Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev 2005;4:CD005053 •• Cochrane review of antiviral therapies for treatment of RRP.
79. Soma M, Albert D. Cidofovir: to use or not to use? Curr Opin Otolaryngol Head Neck Surg 2008;16:86-90 • Current evidence-based review of cidofovir for treatment of RRP..